FDA panel rejects broad use of COVID-19 boosters, approves extra doses for seniors, those at high risk
Dealing the White House a stinging setback, a U.S. government advisory panel on Friday overwhelmingly rejected a plan to administer Pfizer COVID-19 booster shots broadly to the American public, and instead endorsed the extra vaccine dose only for those who are 65 or older or run a high risk of severe disease.
